Pharma Equity Group AS (LTS:0REU) Cash Flow for Dividends: kr0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0REU Pharma Equity Group AS LTS:0REU
18 GF Score
Price kr0.10
! 3 Warning Signs
View Full Analysis

What is Pharma Equity Group AS Cash Flow for Dividends?

Pharma Equity Group AS LTS:0REU 18 Cash Flow for Dividends is kr0.00 Mil as of Dec. 2025. GuruFocus rates LTS:0REU with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Pharma Equity Group AS's cash flow for dividends for the six months ended in Dec. 2025 was kr0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Pharma Equity Group AS Cash Flow for Dividends Related Terms

Pharma Equity Group AS Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Pharma Equity Group AS's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group AS Cash Flow for Dividends Chart

Pharma Equity Group AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharma Equity Group AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0REU
18GF Score
Pharma Equity Group AS LTS:0REU
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Equity Group AS Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of kr0.00 Mil mean?
Pharma Equity Group AS (LTS:0REU) has a Cash Flow for Dividends of kr0.00 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Pharma Equity Group AS and its competitors.
Is Pharma Equity Group AS's Cash Flow for Dividends too high?
Pharma Equity Group AS's current Cash Flow for Dividends is kr0.00 Mil. Overall, Pharma Equity Group AS has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Pharma Equity Group AS's Cash Flow for Dividends compare to VRTX and REGN?
Pharma Equity Group AS's Cash Flow for Dividends of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Pharma Equity Group AS and its competitors. Pharma Equity Group AS's current Cash Flow for Dividends is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (LTS:0REU) has a current Cash Flow for Dividends of kr0.00 Mil. The current Cash Flow for Dividends is kr0.00 Mil. Pharma Equity Group AS's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Pharma Equity Group AS (LTS:0REU), the current Cash Flow for Dividends is kr0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharma Equity Group AS Business Description

Other Exchanges PEG:Denmark
Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
18GF Score

Get the complete analysis for LTS:0REU

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.10
Price